A Director at Aevi Genomic Medicine (NASDAQ: GNMX) is Selling Shares

By Carrie Williams

Yesterday, a Director at Aevi Genomic Medicine (GNMXResearch Report), Sol Barer, sold shares of GNMX for $532.8K.

This is Barer’s first Sell trade following 10 Buy transactions. In addition to Sol Barer, 2 other GNMX executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.23 and a one-year low of $0.11.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children’s Hospital of Philadelphia (CHOP).